Want to see XRN full AI Analyst Report?
Top Page
Chiron Real Estate ate
(NYSE:XRN)
Select Model
Select Model
Rating:55Neutral
Price Target:
$36.00
â–²(1.41% Upside)
Action:Reiterated
Date:08/06/26
Overall score reflects resilient cash generation and revenue growth, but is held back by reported net losses, compressed margins, and meaningful leverage. Technical indicators add pressure due to weak momentum, while valuation is supported by a high dividend yield but tempered by the negative P/E. Earnings-call updates are moderately positive given liquidity and repositioning progress, though execution risk remains.
Positive Factors
Revenue Growth Trend
Sustained top-line growth (TTM ~11%, 2025 ~16%) indicates underlying demand and rent escalators within Chiron’s healthcare portfolio. Durable revenue expansion provides a foundation for reinvestment into higher-return seniors assets and supports cash generation even as the portfolio is repositioned.
Negative Factors
Net Losses and Margin Compression
The swing to net losses and a sharp gross-margin collapse signal pressure from non-operating items, impairments or elevated interest expense. Persistent bottom-line weakness can erode equity, constrain dividend policy and limit flexibility for acquisitions or capex if not reversed.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Trend
Sustained top-line growth (TTM ~11%, 2025 ~16%) indicates underlying demand and rent escalators within Chiron’s healthcare portfolio. Durable revenue expansion provides a foundation for reinvestment into higher-return seniors assets and supports cash generation even as the portfolio is repositioned.
Read all positive factors
Chiron Real Estate ate Key Performance Indicators (KPIs)
Chiron Real Estate ate (XRN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$513.94M
Dividend Yield7.24%
Average Volume (3M)92.86K
Price to Earnings (P/E)―
Beta (1Y)0.58
Revenue Growth6.08%
EPS Growth-815.66%
CountryUS
Employees30
SectorReal Estate
Sector Strength53
IndustryREIT - Healthcare Facilities
Share Statistics
EPS (TTM)-1.12
Shares Outstanding13,234,830
10 Day Avg. Volume74,138
30 Day Avg. Volume92,855
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.92
Price to Sales (P/S)2.90
P/FCF Ratio-57.89
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$41.50Price Target Upside16.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.87
Revenue Forecast (FY)$150.78M
Chiron Real Estate ate Business Overview & Revenue Model
Company Description
Global Medical REIT, Inc. focuses on acquiring specialized healthcare properties designed for medical purposes, subsequently renting them out to medical systems and physician practices. The company was established on March 18, 2011, and operates p...
Chiron Real Estate ate Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call conveyed a constructive strategic pivot toward senior housing with concrete execution: leadership additions, sizable asset sales and acquisitions, equity issuance, improved liquidity and modest improvement in leverage. At the same time, operating growth is modest, net debt/EBITDAre remains elevated, short-term G&A will rise due to hiring, and there is uncertainty and timing risk around fully monetizing outpatient medical assets and achieving market revaluation. Overall, the company demonstrated meaningful progress and tactical wins but still faces execution and valuation headwinds during the transition.Positive Updates
FFO and Core FFO
NAREIT defined FFO per share/unit of $0.88 and core FFO of $1.04 for Q2 2026, indicating positive earnings generation on a per-share basis.
Negative Updates
Modest Same-Store Cash NOI Growth
Same-store cash NOI growth was modest at 0.8% YoY (normalized 1.7%), showing only limited near-term organic operating growth after excluding a prior-year one-time item.
Read all updates
Q2-2026 Updates
Positive
Negative
FFO and Core FFO
NAREIT defined FFO per share/unit of $0.88 and core FFO of $1.04 for Q2 2026, indicating positive earnings generation on a per-share basis.
Read all positive updates
Company Guidance
Management's guidance emphasized disciplined capital allocation and portfolio repositioning with specific financials: Q2 NAREIT FFO per share/unit $0.88 and core FFO $1.04; same‑store cash NOI +0.8% year‑over‑year (or +1.7% on a normalized basis excluding a prior‑year nonrecurring recovery) and same‑store NOI +1.7% normalized; net debt to adjusted EBITDAre 6.0x (down from 6.6x in Q1), leverage just under 40% with no maturities until 2028 and ~$259M of unused credit capacity; they issued $100M of Series C convertible perpetual preferred, closed a $100M May investment, sold seven IRFs for ~$217M at a 7.3% exit cap rate (retaining a small equity stake), are under contract to sell Beaumont for $49M at a 5.9% cap rate, and intend to redeploy proceeds into seniors assets (they cited $421M of seniors investments this quarter plus a $15M land parcel and $5M of mezz loans representing ~33 bps of the portfolio); cash G&A this quarter was $3.8M and management expects a short‑term increase in G&A as new hires ramp but believes costs will align with portfolio size as the transition progresses.Chiron Real Estate ate Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
57
Neutral
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 158.29M | 161.03M | 138.41M | 140.93M | 137.17M | 115.80M |
| Gross Profit | 3.92M | 10.32M | 109.16M | 112.85M | 111.98M | 100.32M |
| EBITDA | 89.53M | 96.73M | 91.47M | 111.64M | 102.89M | 85.35M |
| Net Income | -7.67M | -5.84M | 6.63M | 20.61M | 19.14M | 17.62M |
Balance Sheet | ||||||
| Total Assets | 1.24B | 1.24B | 1.26B | 1.27B | 1.39B | 1.26B |
| Cash, Cash Equivalents and Short-Term Investments | 8.18M | 12.45M | 6.82M | 1.28M | 4.02M | 7.21M |
| Total Debt | 676.75M | 663.74M | 653.59M | 624.19M | 704.65M | 579.86M |
| Total Liabilities | 717.37M | 712.40M | 700.57M | 661.89M | 744.20M | 625.91M |
| Stockholders Equity | 500.21M | 509.77M | 534.13M | 583.58M | 632.98M | 622.78M |
Cash Flow | ||||||
| Free Cash Flow | 25.45M | -8.08M | -25.07M | 58.39M | -79.66M | -132.69M |
| Operating Cash Flow | 74.69M | 73.61M | 70.05M | 68.44M | 76.54M | 68.97M |
| Investing Cash Flow | -43.02M | -60.40M | -45.94M | 67.62M | -137.25M | -194.66M |
| Financing Cash Flow | -28.30M | -10.26M | -21.89M | -143.79M | 62.41M | 127.70M |
Chiron Real Estate ate Technical Analysis
Neutral
35.50
Price Trends
36.35
Negative
35.16
Positive
34.00
Positive
Market Momentum
-0.32
Positive
41.58
Neutral
18.23
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XRN, the sentiment is Neutral. The current price of 35.5 is below the 20-day moving average (MA) of 36.61, below the 50-day MA of 36.35, and above the 200-day MA of 34.00, indicating a neutral trend. The MACD of -0.32 indicates Positive momentum. The RSI at 41.58 is Neutral, neither overbought nor oversold. The STOCH value of 18.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XRN.
Chiron Real Estate ate Risk Analysis
Chiron Real Estate ate disclosed 63 risk factors in its most recent earnings report. Chiron Real Estate ate reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Chiron Real Estate ate Peers Comparison
UnderperformOutperform
Sector (65)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
65 Neutral | $523.15M | 162.04 | 4.96% | 10.14% | 5.24% | ― | |
62 Neutral | $190.93M | 22.22 | 61.18% | 4.55% | 24.57% | 7.81% | |
57 Neutral | $602.48M | 31.01 | 12.79% | 6.80% | 0.75% | 7.29% | |
55 Neutral | $513.94M | -31.80 | 10.22% | 10.01% | 6.08% | -815.66% | |
54 Neutral | $2.15B | -6.70 | -16.22% | 0.43% | 0.39% | -8.95% |
* Real Estate Sector Average
XRN
Chiron Real Estate ate
35.46
4.51
14.55%
DHC
Diversified Healthcare Trust
8.72
5.35
158.98%
CHCT
Community Healthcare
15.58
1.90
13.91%
UHT
Universal Health Realty Income
42.07
6.78
19.22%
STRW
Strawberry Fields REIT Inc
14.44
4.90
51.28%
Chiron Real Estate ate Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Chiron Real Estate posts Q2 profit, pivots to seniors housing
Positive
Aug 5, 2026
On August 5, 2026, Chiron Real Estate reported second-quarter 2026 results showing a sharp turnaround to net income of $63.3 million, or $4.78 per diluted share, versus a small loss a year earlier, even as FFO and Core FFO per share declined. Same...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Chiron Real Estate Names Matthew Whitlock Chief Investment Officer
Positive
Aug 3, 2026
Effective August 3, 2026, Chiron Real Estate Inc. appointed 62-year-old Matthew Whitlock as Chief Investment Officer of both the company and Inter-American Management LLC, bringing extensive senior housing investment experience from Berkshire Resi...
Business Operations and StrategyFinancial Disclosures
Chiron Real Estate updates strategy toward senior housing
Positive
Jul 6, 2026
On July 6, 2026, Chiron Real Estate Inc. updated its investor presentation, outlining a strategic portfolio repositioning toward senior housing operating properties expected to deliver higher returns on invested capital. The company emphasized tha...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsRegulatory Filings and Compliance
Chiron Real Estate completes major hospital portfolio sale
Positive
Jul 2, 2026
On June 29, 2026, Chiron Real Estate Inc. completed the $217 million sale of a portfolio of seven inpatient rehabilitation hospital properties in Pennsylvania, Arizona, Texas, Nevada and Oklahoma to a group of Delaware LLC buyers affiliated with C...
Business Operations and StrategyM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
Chiron Real Estate Expands Portfolio with Landing Alexandria Acquisition
Positive
Jun 2, 2026
On May 28, 2026, Chiron Real Estate Inc., as sole member of the general partner of Chiron Real Estate LP, amended the partnership agreement to create Series C Convertible Preferred Units mirroring its Series C Convertible Preferred Stock, and cont...
Business Operations and StrategyExecutive/Board ChangesDividendsShareholder Meetings
Chiron Real Estate Expands Board, Strengthens Governance Oversight
Positive
May 20, 2026
On May 20, 2026, Chiron Real Estate Inc. expanded its board from six to seven members and appointed veteran real estate investor Charles Fitzgerald as an independent director, with roles on the Compensation and Nominating and Corporate Governance ...
Business Operations and StrategyPrivate Placements and Financing
Chiron Real Estate Raises Capital via Preferred Stock Placement
Neutral
May 8, 2026
On May 6, 2026, Chiron Real Estate Inc. agreed to raise up to $100 million through a private placement of 1,000,000 shares of 6.00% Series C Convertible Perpetual Preferred Stock at $100 per share, with proceeds earmarked for general corporate and...
Business Operations and StrategyDividendsFinancial DisclosuresM&A TransactionsPrivate Placements and Financing
Chiron Real Estate Resets Dividend to Fund Growth
Neutral
May 6, 2026
On May 1 and May 6, 2026, Chiron Real Estate Inc. agreed to acquire three newly built luxury senior housing communities in Alexandria, Virginia and North Bethesda, Maryland for a combined roughly $425 million, all to be operated as seniors housing...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.